The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
Merck has also decided to end the favezelimab clinical development program
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Subscribe To Our Newsletter & Stay Updated
